Gadi_edit.qxp 12/2/09 16:24 Page 88
Transfusion
and not with others (e.g. with plasma and platelets, but not with RBCs), conducted and pathogens are not endemic, in many developing and poor
the benefit of using such devices on a routine basis should be carefully areas – where the prevalence of pathogens is high, blood screening is
considered vis à vis the risk of blood or blood products pathogen lacking or not economically and practically feasible and the risk of
contamination. The feasibility of their usage may vary for different contaminated blood donations is extremely high – thinking outside the
locations. While the damage to the blood components may outweigh the screening box and using inexpensive, easy-to-use pathogen
benefit of using it in blood centres where careful pathogen screening is neutralisation/removal devices, should be considered. ■
1. World Health Organization, Fact sheets. Blood safety and 28. Stramer SL, Current risks of transfusion-transmitted agents: a 49. Kwon JA, Lee H, Lee KN, et al., High diagnostic accuracy of
volunteer donations, 2006. review, Arch Pathol Lab Med, 2007;131:702–7. antigen microarray for sensitive detection of hepatitis C virus
2. Anon, Blood supply and demand, Lancet, 2005;365:2151. 29. Pillonel J, Laperche S, Trends in risk of transfusion-transmitted infection, Clin Chem, 2008;54:424–8.
3. Solheim BG, Pathogen reduction of blood components, Transfus viral infections (HIV, HCV, HBV) in France between 1992 and 50. Ross A,Yomtovian R, Breakthrough technology from Pall
Apher Sci, 2008;39:75–82. 2003 and impact of nucleic acid testing (NAT), Euro Surveill, increases platelet availability and safety, 2005. Available at:
4. Dodd RY, Emerging infections and global blood safety, Dev Biol 2005;10:5–8. www.pall.com/news_articles_38333.asp
(Basel), 2007;127:237–48. 30. Moore A, Herrera G, Nyamongo J, et al., Estimated risk of HIV 51. McCullough J, Pathogen inactivation: a new paradigm for
5. Alter HJ, Stramer SL, Dodd RY, Emerging infectious diseases that transmission by blood transfusion in Kenya, Lancet, preventing transfusion-transmitted infections, Am J Clin Pathol,
threaten the blood supply, Semin Hematol, 2007;44:32–41. 2001;358:657–60. 2007;128:945–55.
6. Busch MP, Wright DJ, Custer B, et al., West Nile virus infections 31. Chatterjee R, Tarwater P, Neogi D, et al., Estimation of HIV 52. FDA Workshop, Minutes of Safety and Efficacy of Methods for
projected from blood donor screening data, United States, 2003, seroprevalence in blood bank camps in Kolkata, India, Transfus Reducing Pathogens in Cellular Blood Products Used in
Emerg Infect Dis, 2006;12:395–402. Med, 2004;14:77–8. Transfusion, 2003.
7. Stramer SL, Fang CT, Foster GA, et al., West Nile virus among 32. Diro E, Alemu S, Yohannes A, Blood safety & prevalence of 53. Grady D, Doctors are cautioned not to give a type of plasma to
blood donors in the United States, 2003 and 2004, N Engl J Med, transfusion transmissible viral infections among donors at the liver patients, New York Times, 2002.
2005;353:451–9. Red Cross Blood Bank in Gondar University Hospital, Ethiop Med 54. Jorquera JI, Safety procedures of coagulation factors,
8. Simon F, Parola P, Grandadam M, et al., Chikungunya infection: J, 2008;46:7–13. Haemophilia, 2007;13(Suppl. 5):41–6.
an emerging rheumatism among travelers returned from Indian 33. Tagny CT, Mbanya D, Tapko JB, et al., Blood safety in Sub- 55. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al., In vitro
Ocean islands. Report of 47 cases, Medicine (Baltimore), Saharan Africa: a multi-factorial problem, Transfusion, evaluation of metabolic changes and residual platelet
2007;86:123–37. 2008;48:1256–61. responsiveness in photochemical treated and gamma-irradiated
9. Parola P, de LX, Jourdan J, et al., Novel chikungunya virus variant 34. Shang G, Seed CR, Wang F, et al., Residual risk of transfusion- single-donor platelet concentrates during long-term storage,
in travelers returning from Indian Ocean islands, Emerg Infect Dis, transmitted viral infections in Shenzhen, China, 2001 through Transfusion, 2007;47:653–65.
2006;12:1493–9. 2004, Transfusion, 2007;47:529–39. 56. National Institute of Environmental Health Sciences, National
10. Piron M, Verges M, Munoz J, et al., Seroprevalence of 35. Ganczak M.,Barss P, Nosocomial HIV infection: epidemiology and Toxicity Program Report on Carcinogen, 2002, 10th report on
Trypanosoma cruzi infection in at-risk blood donors in Catalonia prevention—a global perspective, AIDS Rev, 2008;10:47–61. carcinogens: Research Triangle Park, NC, US.
(Spain), Transfusion, 2008; in press. 36. Polizzotto MN, Wood EM, Ingham H, et al., Reducing the risk of 57. Yokoyama T, Murai K, Murozuka T, et al., Removal of small non-
11. Hochedez P, Hausfater P, Jaureguiberry S, et al., Cases of transfusion-transmissible viral infection through blood donor enveloped viruses by nanofiltration, Vox Sang, 2004;86:225–9.
chikungunya fever imported from the islands of the South West selection: the Australian experience 2000 through 2006, 58. Burnouf T.,Radosevich M, Nanofiltration of plasma-derived
Indian Ocean to Paris, France, Euro Surveill, 2007;12. Transfusion, 2008;48:55–63. biopharmaceutical products, Haemophilia, 2003;9:24–37.
12. Centers for Disease Control and Prevention, Detection of West 37. Nebie KY, Olinger CM, Kafando E, et al., Lack of knowledge 59. Kreil TR, Wieser A, Berting A, et al., Removal of small
Nile virus in blood donations—Puerto Rico, 2007, MMWR Morb among blood donors in Burkina Faso (West Africa); potential nonenveloped viruses by antibody-enhanced nanofiltration during
Mortal Wkly Rep, 2008;57:577–80. obstacle to transfusion security, Transfus Clin Biol, the manufacture of plasma derivatives, Transfusion,
13. Sanchez-Guerrero SA, Romero-Estrella S, Rodriguez-Ruiz A, et al., 2007;14:446–52. 2006;46:1143–51.
Detection of West Nile virus in the Mexican blood supply, 38. Egah DZ, Banwat EB, Audu ES. et al., Hepatitis B surface 60. Allegrezza A, Ireland T, Kools W, Membranes in the
Transfusion, 2006;46:111–17. antigen, hepatitis C and HIV antibodies in a low-risk blood donor Biopharmaceutical Industry, In: Peinemann KV and Pereira-Nunes
14. Hollinger FB, Kleinman S, Transfusion transmission of West Nile group, Nigeria, East Mediterr Health J, 2007;13:961–6. S (eds), Membranes for Life Sciences, Weinheim (GmbH): Wiley-
virus: a merging of historical and contemporary perspectives, 39. Velati C, Romano L, Fomiatti L, et al., Impact of nucleic acid VCH, 2008;4–91.
Transfusion, 2003;43:992–7. testing for hepatitis B virus, hepatitis C virus, and human 61. Borkow G.,Gabbay J, Putting copper into action: copper-
15. Cameron C, Reeves J, Antonishyn N, et al., West Nile virus in immunodeficiency virus on the safety of blood supply in Italy: a 6- impregnated products with potent biocidal activities, FASEB J,
Canadian blood donors, Transfusion, 2005;45:487–91. year survey, Transfusion, 2008, in press. 2004;18:1728–30.
16. Biggerstaff BJ.,Petersen LR, Estimated risk of West Nile virus 40. Montag T, Strategies of bacteria screening in cellular blood 62. Gabbay J, Mishal J, Magen E, et al., Copper oxide impregnated
transmission through blood transfusion during an epidemic in components, Clin Chem Lab Med, 2008;46:926–32. textiles with potent biocidal activities, Journal of Industrial
Queens, New York City, Transfusion, 2002;42:1019–26. 41. Nubling CM, Unkelbach U, Chudy M, et al., Effect of viral nucleic Textiles, 2006;35:323–35.
17. Stramer SL, Reacting to an emerging safety threat: West Nile acid testing on contamination frequency of manufacturing plasma 63. Borkow G, Sidwell RW, Smee DF, et al., Neutralizing viruses in
virus in North America, Dev Biol (Basel), 2007;127:43–58. pools, Transfusion, 2008;48:822–6. suspensions by copper oxide based filters, Antimicrob Agents
18. Walther-Wenke G, Incidence of bacterial transmission and 42. Schmidt M, Themann A, Drexler C, et al., Blood donor screening Chemother, 2007;51:2605–7.
transfusion reactions by blood components, Clin Chem Lab Med, for parvovirus B19 in Germany and Austria, Transfusion, 64. Borkow G, Lara HH, Covington CY, et al., Deactivation of human
2008;46:919–25. 2007;47:1775–82. immunodeficiency virus type 1 in medium by copper oxide-
19. Tayou TC, Mbanya D, Garraud O, et al., Blood safety: malaria 43. Shimoyama R, Transfusion-transmitted diseases, Hokkaido Igaku containing filters, Antimicrob Agents Chemother,
and blood donation in Africa, Transfus Clin Biol, 2007;14:481–6. Zasshi, 2008;83:5–21. 2008;52:518–25.
20. Prati D, Transmission of hepatitis C virus by blood transfusions 44. Kretzschmar E, Chudy M, Nubling CM, et al., First case of 65. Borkow G.,Gabbay J, Copper as a biocidal tool, Curr Med Chem,
and other medical procedures: a global review, J Hepatol, hepatitis C virus transmission by a red blood cell concentrate 2005;12:2163–75.
2006;45:607–16. after introduction of nucleic acid amplification technique 66. Karlstrom AR.,Levine RL, Copper inhibits the protease from
21. Ahmed SG, Ibrahim UA, Hassan AW, Adequacy and pattern of screening in Germany: a comparative study with various assays, human immunodeficiency virus 1 by both cysteine-dependent and
blood donations in north-eastern Nigeria: the implications for Vox Sang, 2007;92:297–301. cysteine-independent mechanisms, Proc Natl Acad Sci
blood safety, Ann Trop Med Parasitol, 2007;101:725–31. 45. Shan H, Ren FR, Zhao HY, et al., A multi-Chinese blood center U S A, 1991;88:5552–6.
22. Whyte G, Improved safety of clinical blood transfusion in four study testing serologic-negative donor samples for hepatitis C 67. Turnlund JR, Human whole-body copper metabolism, Am J Clin
provinces of China 1997–2005, Dev Biol (Basel), virus and human immunodeficiency virus with nucleic acid Nutr, 1998;67:960S–964S.
2007;127:197–204. testing, Transfusion, 2007;47:2011–16. 68. Ahmed MJ, Jahan I, Banoo S, A simple spectrophotometric
23. Zhu YM, Blood safety—a focus on plasma derivatives in 46. Maresch C, Schluter PJ, Wilson AD, et al., Residual infectious method for the determination of copper in industrial,
Mainland China, Dev Biol (Basel), 2007;127:175–81. disease risk in screened blood transfusion from a high-prevalence environmental, biological and soil samples using
24. Tadokoro K, The new Japanese blood law: its impact on blood population: Santa Catarina, Brazil, Transfusion, 2008;48:273–81. 2,5-dimercapto-1,3,4-thiadiazole, Anal Sci, 2002;18:805–10.
safety and usage, Dev Biol (Basel), 2007;127:161–8. 47. Murphy WG, Foley M, Doherty C, et al., Screening platelet 69. Yilmaz ME, Kiraz M, Kara IH, The evaluation of serum zinc and
25. Seitz R, The European Blood Directive—its role in blood safety, concentrates for bacterial contamination: low numbers of copper levels in hemodialysis patients in Southeast Turkey, Dial
Dev Biol (Basel), 2007;127:147–52. bacteria and slow growth in contaminated units mandate an Transplant, 2000;29:718–21.
26. Dodd RY, Current risk for transfusion transmitted infections, Curr alternative approach to product safety, Vox Sang, 2008, in press. 70. Linder M, Biochemistry and molecular biology of copper in
Opin Hematol, 2007;14:671–6. 48. Dreier J, Stormer M, Kleesiek K, Real-time polymerase chain mammals, 2002;1-32.
27. Bryant BJ, Klein HG, Pathogen inactivation: the definitive reaction in transfusion medicine: applications for detection of 71. Massaro EJ (ed), Handbook of copper pharmacology and
safeguard for the blood supply, Arch Pathol Lab Med, bacterial contamination in blood products, Transfus Med Rev, toxicology, Totowa, NJ: Humana Press, 2002.
2007;131:719–33. 2007;21:237–54.
88 EUROPEAN HAEMATOLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100